Biotage Balance Sheet Health
Financial Health criteria checks 6/6
Biotage has a total shareholder equity of SEK3.8B and total debt of SEK150.0M, which brings its debt-to-equity ratio to 3.9%. Its total assets and total liabilities are SEK4.9B and SEK1.1B respectively. Biotage's EBIT is SEK369.0M making its interest coverage ratio 23.1. It has cash and short-term investments of SEK370.0M.
Key information
3.9%
Debt to equity ratio
SEK 150.00m
Debt
| Interest coverage ratio | 23.1x |
| Cash | SEK 370.00m |
| Equity | SEK 3.81b |
| Total liabilities | SEK 1.06b |
| Total assets | SEK 4.87b |
Recent financial health updates
Biotage (STO:BIOT) Has A Pretty Healthy Balance Sheet
Feb 08
Does Biotage (STO:BIOT) Have A Healthy Balance Sheet?
Jul 12These 4 Measures Indicate That Biotage (STO:BIOT) Is Using Debt Safely
Mar 12Biotage (STO:BIOT) Seems To Use Debt Rather Sparingly
Dec 03Biotage (STO:BIOT) Could Easily Take On More Debt
Sep 03Recent updates
Are Investors Undervaluing Biotage AB (publ) (STO:BIOT) By 48%?
Nov 16Earnings Miss: Biotage AB (publ) Missed EPS By 15% And Analysts Are Revising Their Forecasts
Oct 26Investors Interested In Biotage AB (publ)'s (STO:BIOT) Earnings
Sep 17Biotage AB (publ) Just Missed EPS By 7.7%: Here's What Analysts Think Will Happen Next
Jul 19Are Investors Undervaluing Biotage AB (publ) (STO:BIOT) By 39%?
Jun 08Is Biotage AB (publ) (STO:BIOT) Potentially Undervalued?
May 21Revenue Beat: Biotage AB (publ) Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates
Apr 28Biotage's (STO:BIOT) Dividend Will Be SEK1.60
Apr 17Biotage AB (publ) Just Beat EPS By 53%: Here's What Analysts Think Will Happen Next
Apr 08Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60
Apr 03Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60
Mar 04Weak Statutory Earnings May Not Tell The Whole Story For Biotage (STO:BIOT)
Feb 22Subdued Growth No Barrier To Biotage AB (publ) (STO:BIOT) With Shares Advancing 32%
Feb 21Biotage AB (publ) Just Recorded A 53% EPS Beat: Here's What Analysts Are Forecasting Next
Feb 18Biotage (STO:BIOT) Has A Pretty Healthy Balance Sheet
Feb 08Investors Still Waiting For A Pull Back In Biotage AB (publ) (STO:BIOT)
Jan 07At kr124, Is It Time To Put Biotage AB (publ) (STO:BIOT) On Your Watch List?
Dec 08Estimating The Intrinsic Value Of Biotage AB (publ) (STO:BIOT)
Oct 27Does Biotage (STO:BIOT) Have A Healthy Balance Sheet?
Jul 12An Intrinsic Calculation For Biotage AB (publ) (STO:BIOT) Suggests It's 26% Undervalued
Jun 08Biotage (STO:BIOT) Ticks All The Boxes When It Comes To Earnings Growth
May 24Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's
Apr 05These 4 Measures Indicate That Biotage (STO:BIOT) Is Using Debt Safely
Mar 12Is It Too Late To Consider Buying Biotage AB (publ) (STO:BIOT)?
Feb 21Are Biotage AB (publ) (STO:BIOT) Investors Paying Above The Intrinsic Value?
Jan 06Biotage (STO:BIOT) Seems To Use Debt Rather Sparingly
Dec 03Is Now The Time To Look At Buying Biotage AB (publ) (STO:BIOT)?
Oct 27Estimating The Fair Value Of Biotage AB (publ) (STO:BIOT)
Oct 07Biotage (STO:BIOT) Could Easily Take On More Debt
Sep 03Is There Now An Opportunity In Biotage AB (publ) (STO:BIOT)?
Jul 10A Look At The Fair Value Of Biotage AB (publ) (STO:BIOT)
Jun 25Do Biotage's (STO:BIOT) Earnings Warrant Your Attention?
May 28Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's
Apr 23Financial Position Analysis
Short Term Liabilities: BIOT's short term assets (SEK1.2B) exceed its short term liabilities (SEK648.0M).
Long Term Liabilities: BIOT's short term assets (SEK1.2B) exceed its long term liabilities (SEK407.0M).
Debt to Equity History and Analysis
Debt Level: BIOT has more cash than its total debt.
Reducing Debt: BIOT's debt to equity ratio has reduced from 12.6% to 3.9% over the past 5 years.
Debt Coverage: BIOT's debt is well covered by operating cash flow (270.7%).
Interest Coverage: BIOT's interest payments on its debt are well covered by EBIT (23.1x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 01:52 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Biotage AB (publ) is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Samuel England | Berenberg |
| Odysseas Manesiotis | Berenberg |
| Marcus Bellander | Carnegie Investment Bank AB |